The Year in Heart Failure
1st Edition
Published on 28. February 2005
Book
Hardback
296 pages
978-1-904392-38-5 (ISBN)
Description
This has been an important year for the study of heart failure with advances being made on a number of fronts, in pharmacological therapy, surgery and the use of mechanical devices. In addition, we are now in a position to properly evaluate the results of a number of major trials and in this volume the editor presents a critical analysis of these findings. Included here are discussions of nine recent studies including the CHARM, EPHESUS, LIDO and OVERTURE trials, the latest studies of beta-blockers (COMET and CAPRICORN), TNF alpha-inhibitors (ATTACH) and endothelin antagonists (RITZ-4). Also reviewed are the recent studies of devices used in resynchronisation therapy (MIRACLE and COMPANION), cardiac splints (ACORN) and also surgical procedures such as CABG (the STITCH trial).
More details
Language
English
Place of publication
Oxford
United Kingdom
Target group
Professional and scholarly
Cardiologists, general physicians, doctors in training
Dimensions
Height: 229 mm
Width: 152 mm
Weight
703 gr
ISBN-13
978-1-904392-38-5 (9781904392385)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Persons
Content
EPIDEMIOLOGY - Harlan M. Krumholz
Long-Term Trends in the Incidence of and Survival with Heart Failure.
Diastolic Heart Failure in the Community: Clinical Profile, Natural History, Therapy, and Impact of Proposed Diagnostic Criteria.
PATHOPHYSIOLOGY, NEW ASPECTS - James Young
Heart failure: A Review
Autologous Myoblast Infusions
Diastolic Heart Failure
THE PROMISE OF NEW PHARMACOLOGIC THERAPIES: UNFULFILLED Kirkwood Adams
Levosimendan (LIDO) Study.
Omapatrilat (OVERTURE).
TNF alpha inhibitors (ATTACH) Trial.
Endothelin antagonists (RITZ-4).
Eplenerone (EPHESUS)
Candesartan in Heart Failure Trials (CHARM)
Valsartan in MI (VALIANT)
Beta blockers (COMET, CAPRICORN)
DEVICES IN HEART FAILURE: NEW APPROACHES - Mandeep Mehra
ICD-MADIT II
Resynchronization therapy: MIRACLE, COMPANION
Ventricular assist devices, i) Bridge to transplant, ii) Destination therapy
Should we pace the RV? DAVID trial
Cardiac splints (ACORN)
SURGICAL TREATMENTS AND APPROACHES - Patrick McCarthy
CABG The STITCH trial
MVR
Infarct exclusion
Nontransplant surgical alternatives in heart failure.
NOVEL APPROACHES TO HEART FAILURE THERAPY
Exercise in Heart Failure: Is it beneficial? Steven Keteyian,
Sleep disorders l - Mark E. Dunlap
GENETIC MARKERS IN HEART FAILURE
DIASTOLIC DYSFUNCTION - IS IT REALLY HEART FAILURE
Long-Term Trends in the Incidence of and Survival with Heart Failure.
Diastolic Heart Failure in the Community: Clinical Profile, Natural History, Therapy, and Impact of Proposed Diagnostic Criteria.
PATHOPHYSIOLOGY, NEW ASPECTS - James Young
Heart failure: A Review
Autologous Myoblast Infusions
Diastolic Heart Failure
THE PROMISE OF NEW PHARMACOLOGIC THERAPIES: UNFULFILLED Kirkwood Adams
Levosimendan (LIDO) Study.
Omapatrilat (OVERTURE).
TNF alpha inhibitors (ATTACH) Trial.
Endothelin antagonists (RITZ-4).
Eplenerone (EPHESUS)
Candesartan in Heart Failure Trials (CHARM)
Valsartan in MI (VALIANT)
Beta blockers (COMET, CAPRICORN)
DEVICES IN HEART FAILURE: NEW APPROACHES - Mandeep Mehra
ICD-MADIT II
Resynchronization therapy: MIRACLE, COMPANION
Ventricular assist devices, i) Bridge to transplant, ii) Destination therapy
Should we pace the RV? DAVID trial
Cardiac splints (ACORN)
SURGICAL TREATMENTS AND APPROACHES - Patrick McCarthy
CABG The STITCH trial
MVR
Infarct exclusion
Nontransplant surgical alternatives in heart failure.
NOVEL APPROACHES TO HEART FAILURE THERAPY
Exercise in Heart Failure: Is it beneficial? Steven Keteyian,
Sleep disorders l - Mark E. Dunlap
GENETIC MARKERS IN HEART FAILURE
DIASTOLIC DYSFUNCTION - IS IT REALLY HEART FAILURE